Disposition of 4151 shares by Troy Wichterman of BioLife Solutions at 25.0 subject to Rule 16b-3
| BLFS Stock | USD 20.73 0.16 0.77% |
Slightly above 62% of BioLife Solutions' investor base is looking to short. The analysis of overall sentiment of trading BioLife Solutions stock suggests that many investors are alarmed at this time. BioLife Solutions' investing sentiment can be driven by a variety of factors including economic data, BioLife Solutions' earnings reports, geopolitical events, and overall market trends.
Filed transaction by BioLife Solutions Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
BioLife Solutions Fundamental Analysis
We analyze BioLife Solutions' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Solutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Solutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
BioLife Solutions is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
BioLife Solutions Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLife Solutions stock to make a market-neutral strategy. Peer analysis of BioLife Solutions could also be used in its relative valuation, which is a method of valuing BioLife Solutions by comparing valuation metrics with similar companies.
Peers
BioLife Solutions Related Equities
| ATRC | AtriCure | 3.27 | ||||
| CDNA | CareDx | 1.98 | ||||
| ANGO | AngioDynamics | 1.29 | ||||
| COO | Cooper Companies, | 0.82 | ||||
| RGNX | Regenxbio | 0.48 | ||||
| AXGN | Axogen | 0.95 | ||||
| ATR | AptarGroup | 1.57 | ||||
| VCEL | Vericel Corp | 2.02 | ||||
| CYRX | Cryoport | 5.87 |
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.